natgillin/translations-raw huggingface dataset:
Do this even if the vials contain unused amounts of medicine or Water for Injections as these are for single use only.
Učinite to čak i ako je u bočicama preostalo nešto neupotrijebljenog lijeka ili vode za injekcije jer su one namijenjene samo za jednokratnu uporabu.
Do this even if the vials contain unused amounts of medicine or Water for Injections as these are for single use only.
Učinite to čak i ako u bočicama preostane određena količina neupotrijebljenog lijeka ili vode za injekcije, jer su bočice namijenjene isključivo za jednokratnu uporabu.
Do this in front of a mirror if it helps.
Ako Vam to pomaže, stanite pred ogledalo.
Do this in front of a mirror if it helps.
Koristite se ogledalom, ako Vam to pomaže.
Do this no matter when your period begins or ends.
Učinite prema uputi bez obzira na to kada Vam menstruacija započne ili završi.
Do this straight away when you have mixed the dose.
Napravite to čim ste zamiješali dozu.
Do this ten times.
Napravite to deset puta.
Do this until a drop of Humalog BASAL comes out of the needle.
Pritišćite sve dok se na vrhu igle ne pojavi kapljica lijeka Humalog BASAL.
Do this until a drop of Humalog Mix25 comes out of the needle.
Pritišćite sve dok se na vrhu igle ne pojavi kapljica lijeka Humalog Mix25.
Do this until a drop of Liprolog Basal comes out of the needle.
Pritišćite sve dok se na vrhu igle ne pojavi kapljica lijeka Liprolog Basal.
Do this until all the air is gone and there is 1 ml of reconstituted solution in the syringe.
Ponavljajte to sve dok zrak ne nestane te se ne pojavi 1 ml pripremljene otopine u štrcaljki.
Do this until the levels of AUBAGIO in your blood are low enough - your doctor will check this.
Koristite je sve dok razine lijeka AUBAGIO u Vašoj krvi ne budu dovoljno niske - to će provjeriti Vaš liječnik.
Do visually inspect the dissolved liquid for particles and/or discolouration.
Obavezno vizualno pregledajte otopinu sadrži li čestice i/ili je li promijenila boju.
Do visually inspect the reconstituted solution for particulate matter and/or discoloration.
Vizualno pregledajte sadrži li rekonstituirana otopina čestice i/ili je li promijenila boju.
Do wait for the injection to finish before releasing pressure.
Pričekajte završetak davanja injekcije prije otpuštanja pritiska.
Do you need to receive vaccines (live vaccines)?
Trebate li primiti cjepiva (živa cjepiva)?
Doasge and frequency
Doza i učestalost primjene
dobutamine (used for the chronic heart disease),
dobutamin (koristi se za kroničnu bolest srca),
Dobutamine HCl
dobutaminklorid
Dobutamine hydrochloride
dobutaminklorid
Docetaxel
Docetaksel
Docetaxel + Cis + 5-FU
Docetaksel + Cis + 5-FU
Docetaxel + Cis + 5-FU n = 255
Docetaksel + Cis + 5-FU
Docetaxel +Cis+5-FU n=255
Cis + 5-FU n = 246
Docetaxel 20 mg/0.72 ml vial:
Docetaksel 20 mg/0,72 ml bočica:
Docetaxel 30 mg/m2 administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles.
Docetaksel 30 mg/m2 primijenjen tjedno prvih 5 tjedana u ciklusu liječenja od 6 tjedana, tijekom 5 ciklusa.
Docetaxel 30 mg/m² administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles.
Docetaksel 30 mg/m2 primijenjen tjedno prvih 5 tjedana u ciklusu liječenja od 6 tjedana, tijekom 5 ciklusa.
Docetaxel 47% 35%
Docetaksel 47% 35
Docetaxel 75 mg/m2 every
Docetaksel 75 mg/m2 svaka
Docetaxel 75 mg/m2 every 3 weeks for 10 cycles.
Docetaksel 75 mg/m2 svaka 3 tjedna tijekom 10 ciklusa.
Docetaxel 75 mg/m2 every 3 weeks for 10 cycles.
Docetaksel 75 mg/m2 svaka tri tjedna tijekom 10 ciklusa.
Docetaxel 75 mg/m² every 3 weeks for 10 cycles.
Docetaksel 75 mg/m2 svaka 3 tjedna tijekom 10 ciklusa.
Docetaxel 80 mg/2.88 ml vial:
Docetaksel 80 mg/2.88 ml bočica:
Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion
Docetaxel Accord 160 mg/8 ml koncentrat za otopinu za infuziju
Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion docetaxel
Docetaxel Accord 160 mg/8 ml koncentrat za otopinu za infuziju docetaksel
Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Accord 160 mg/8 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku otopinu.
Docetaxel Accord 160 mg/8 ml sterile concentrate docetaxel
Docetaxel Accord 160 mg/8 ml sterilni koncentrat docetaksel
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion
Docetaxel Accord 20 mg/1 ml koncentrat za otopinu za infuziju
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion docetaxel
Docetaxel Accord 20 mg/1 ml koncentrat za otopinu za infuziju docetaksel
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Accord 20 mg/1 ml koncentrat za otopinu za infuziju NE ZAHTJEVA prethodno razrjeđivanje s otapalom i spreman je za dodavanje infuzijskoj otopini.
Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion
Docetaxel Accord 80 mg/4 ml koncentrat za otopinu za infuziju
Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion docetaxel
Docetaxel Accord 80 mg/4 ml koncentrat za otopinu za infuziju docetaksel
Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Accord 80 mg/4 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku otopinu.
Docetaxel Accord 80 mg/4 ml sterile concentrate docetaxel
Docetaxel Accord 80 mg/4 ml sterilni koncentrat docetaksel
Docetaxel Accord concentrate for solution for infusion is a clear pale yellow to brownish-yellow solution.
Docetaxel Accord koncentrat za otopinu za infuziju je prozirna svijetložuta do smeđežuta otopina.
Docetaxel Accord concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Accord koncentrat za otopinu za infuziju NE ZAHTJEVA prethodno razrjeđivanje s otapalom i spreman je za dodavanje infuzijskoj otopini.
Docetaxel Accord has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
Docetaxel Accord Vam je propisao liječnik za liječenje karcinoma dojke, posebnih oblika karcinoma pluća (karcinom nemalih stanica pluća), karcinoma prostate, karcinoma želuca ili karcinoma glave i vrata:
Docetaxel as single agent
Docetaksel u monoterapiji
Docetaxel blocks a stage of cell division, whereby the internal ‘skeleton’ is dismantled to allow the cell to divide.
Docetaxel blokira stadije diobe stanica pri čemu se unutarnji „kostur” rastavlja kako bi se omogućilo dijeljenje stanica.
Docetaxel dose reductions may be applied based upon the grade of toxicity experienced by the patient.
Doza docetaksela može se smanjivati u skladu sa stupnjem toksičnosti koja se razvije kod bolesnika.
Docetaxel has been shown to be both embryotoxic and foetotoxic in rabbits and rats, and to reduce fertility in rats.
Docetaksel je pokazao embriotoksičnst i fetotoksičnost u kunića i štakora, kao i smanjenje plodnosti u štakora.
Docetaxel in combination with doxorubicin and cyclophosphamide: adjuvant therapy
Docetaksel u kombinaciji s doksorubicinom i ciklofosfamidom: adjuvantno liječenje
Docetaxel in combination with doxorubicin and cyclophosphamide: adjuvant therapy
Docetaxel u kombinaciji s doksorubicinom i ciklofosfamidom: adjuvantno liječenje
Docetaxel in combination with trastuzumab was studied for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2, and who previously had not received chemotherapy for metastatic disease.
Docetaksel u kombinaciji s trastuzumabom ispitivao se u liječenju bolesnika s metastatskim karcinomom dojke i pojačanom ekspresijom HER2 na tumorskim stanicama koji nisu ranije primali kemoterapiju za metastatsku bolest.
Docetaxel infusion solution is supersaturated, therefore may crystallise over time.
Infuzijska otopina docetaksela je prezasićena, stoga, tijekom vremena može doći do kristalizacije.
Docetaxel infusion solution is supersaturated, therefore may crystallize over time.
Infuzijska otopina docetaksela je prezasićena, stoga, tijekom vremena može doći do kristalizacije.
Docetaxel is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Accord solutions.
Docetaksel je antineoplastična tvar te se, kao što je slučaj i sa svim ostalim potencijalno toksičnim spojevima, mora s njime oprezno rukovati u pripremi otopine Docetaxel Accord.
Docetaxel is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing its solutions.
Docetaksel je antineoplastična tvar te se njime, kao što je slučaj i sa svim ostalim potencijalno toksičnim spojevima, mora oprezno rukovati u pripremi Docetaxel otopina.
DOCETAXEL KABI 120 mg/6 ml concentrate for solution for infusion
DOCETAXEL KABI 120 mg/6 ml koncentrat za otopinu za infuziju
DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusion
DOCETAXEL KABI 160 mg/8 ml koncentrat za otopinu za infuziju
DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusion
DOCETAXEL KABI 180 mg/9 ml koncentrat za otopinu za infuziju
DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusion Docetaxel
DOCETAXEL KABI 180 mg/9 ml koncentrat za otopinu za infuziju docetaksel
DOCETAXEL KABI 20 mg/1 ml concentrate for solution for infusion
DOCETAXEL KABI 20 mg/1 ml koncentrat za otopinu za infuziju
DOCETAXEL KABI 20 mg/1 ml concentrate for solution for infusion Docetaxel
DOCETAXEL KABI 20 mg/1 ml koncentrat za otopinu za infuziju docetaksel
DOCETAXEL KABI 80 mg/4 ml concentrate for solution for infusion
DOCETAXEL KABI 80 mg/4 ml koncentrat za otopinu za infuziju
DOCETAXEL KABI 80 mg/4 ml concentrate for solution for infusion Docetaxel
DOCETAXEL KABI 80 mg/4 ml koncentrat za otopinu za infuziju docetaksel
DOCETAXEL KABI 80 mg/4 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
DOCETAXEL KABI 80 mg/4 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku otopinu.
DOCETAXEL KABI as single agent
DOCETAXEL KABI u monoterapiji
DOCETAXEL KABI concentrate for solution for infusion is a clear, colourless to pale yellow solution.
DOCETAXEL KABI koncentrat za otopinu za infuziju je bistra, bezbojna do blijedo žuta otopina.
DOCETAXEL KABI has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
DOCETAXEL KABI Vam je propisao liječnik za liječenje karcinoma dojke, posebnih oblika karcinoma pluća (karcinom nemalih stanica pluća), karcinoma prostate, karcinoma želuca ili karcinoma glave i vrata:
DOCETAXEL KABI in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
DOCETAXEL KABI je u kombinaciji s cisplatinom i 5-fluorouracilom indiciran za liječenje bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja koji nisu prethodno primali kemoterapiju za metastatsku bolest.
DOCETAXEL KABI in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
DOCETAXEL KABI je u kombinaciji s cisplatinom indiciran za liječenje bolesnika s neoperabilnim, lokalno uznapredovalim ili metastatskim karcinomom nemalih stanica pluća koji nisu ranije primali kemoterapiju za tu bolest.
DOCETAXEL KABI in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.
DOCETAXEL KABI je u kombinaciji s trastuzumabom indiciran za liječenje bolesnika s metastatskim karcinomom dojke i prekomjerno izraženim HER2 koji nisu ranije primali kemoterapiju za metastatsku bolest.
DOCETAXEL KABI monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
DOCETAXEL KABI je kao monoterapija indiciran za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke nakon neuspjeha citotoksične terapije.
DOCETAXEL KABI must NOT be administered if you are pregnant unless clearly indicated by your doctor.
DOCETAXEL KABI NE smijete primati ako ste trudni ili ako planirate trudnoću, osim ako Vam ga je izričito propisao liječnik.
Docetaxel must not be used in patients with severe liver impairment since there is no data available (see sections 4.2 and 4.4).
Bolesnici s teškim oštećenjem jetre (vidjeti dijelove 4.2. i 4.4).
Docetaxel must not be used in patients with severe liver impairment since there is no data available (see sections 4.2 and 4.4).
Bolesnici s teškim oštećenjem jetrei (vidjeti dijelove 4.2. i 4.4).
Docetaxel Mylan 20 mg/1 ml concentrate for solution for infusion
Docetaxel Mylan 20 mg/1 ml koncentrat za otopinu za infuziju
Docetaxel Mylan 20 mg/1 ml concentrate for solution for infusion docetaxel
Docetaxel Mylan 20 mg/1 ml koncentrat za otopinu za infuziju docetaksel
Docetaxel Mylan 20 mg/1 ml sterile concentrate docetaxel
Docetaxel Mylan 20 mg/1 ml sterilni koncentrat docetaksel
Docetaxel Mylan 200 mg/10 ml concentrate for solution for infusion
Docetaxel Mylan 200 mg/10 ml koncentrat za otopinu za infuziju
Docetaxel Mylan 200 mg/10 ml concentrate for solution for infusion docetaxel
Docetaxel Mylan 200 mg/10 ml koncentrat za otopinu za infuziju docetaksel
Docetaxel Mylan 200 mg/10 ml sterile concentrate docetaxel
Docetaxel Mylan 200 mg/10 ml sterilni koncentrat docetaksel
Docetaxel Mylan 80 mg/4 ml concentrate for solution for infusion
Docetaxel Mylan 80 mg/4 ml koncentrat za otopinu za infuziju
Docetaxel Mylan 80 mg/4 ml concentrate for solution for infusion docetaxel
Docetaxel Mylan 80 mg/4 ml koncentrat za otopinu za infuziju docetaksel
Docetaxel Mylan 80 mg/4 ml sterile concentrate docetaxel
Docetaxel Mylan 80 mg/4 ml sterilni koncentrat docetaksel
Docetaxel Mylan concentrate for solution for infusion is a pale yellow to brownish-yellow solution.
Docetaxel Mylan koncentrat za otopinu za infuziju je blijedo žuta do smeđežuta otopina.
Docetaxel Mylan has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
Docetaxel Mylan Vam je propisao liječnik za liječenje karcinoma dojke, posebnih oblika karcinoma pluća (karcinom nemalih stanica pluća), karcinoma prostate, karcinoma želuca ili karcinoma glave i vrata:
Docetaxel Mylan is indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.
Docetaxel Mylan je indiciran za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom nemalih stanica pluća nakon neuspjeha prethodne kemoterapije.
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with mestatic prostate cancer.
Farmakokinetika docetaksela u prisustvu prednizona ispitivala se u bolesnika s metastatskim karcinomom prostate.
Docetaxel plus trastuzumab1 n = 92
Docetaksel plus trastuzumab1 n = 92
Docetaxel should be administered when the neutrophil count is  1,500 cells/mm3.
Docetaksel treba primjenjivati kad je broj neutrofila ≥ 1500 stanica/mm3.
Docetaxel Teva 20 mg/0.72 ml concentrate and solvent for solution for infusion
Docetaksel Teva 20 mg/0,72 ml koncentrat i otapalo za otopinu za infuziju
Docetaxel Teva 20 mg/0.72 ml concentrate for solution for infusion docetaxel
Docetaksel Teva 20 mg/0,72 ml koncentrat za otopinu za infuziju docetaksel
Docetaxel Teva 20 mg/0.72 ml concentrate for solution for infusion is a clear viscous, yellow to brown-yellow solution containing 27.73 mg/ml docetaxel (anhydrous) in polysorbate 80.
Docetaksel Teva 20 mg/0.72 ml koncentrat za otopinu za infuziju bistra je viskozna, žuta do žutosmeđa otopina koja sadrži 27,73 mg/ml docetaksela (bezvodnog) u polisorbatu 80.
Docetaxel Teva 80 mg/2.88 ml concentrate and solvent for solution for infusion
Docetaksel Teva 80 mg/2.88 ml koncentrat i otapalo za otopinu za infuziju
Docetaxel Teva 80 mg/2.88 ml concentrate and solvent for solution for infusion docetaxel
Docetaksel Teva 80 mg/2.88 ml koncentrat i otapalo za otopinu za infuziju docetaksel
Docetaxel Teva 80 mg/2.88 ml concentrate for solution for infusion docetaxel
Docetaksel Teva 80 mg/2.88 ml koncentrat i otapalo za otopinu za infuziju docetaksel
Docetaxel Teva 80 mg/2.88 ml concentrate for solution for infusion is a clear viscous, yellow to brown-yellow solution containing 27.73 mg/ml docetaxel (anhydrous) in polysorbate 80.
Docetaksel Teva 80 mg/2.88 ml koncentrat za otopinu za infuziju bistra je viskozna, žuta do žutosmeđa otopina koja sadrži 27,73 mg/ml docetaksela (bezvodnog) u polisorbatu 80.
Docetaxel Teva 80 mg/2.88 ml vial
Docetaksel Teva 80 mg/2.88 ml bočica
Docetaxel Teva has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
Docetaksel Teva Vam je propisao liječnik za liječenje karcinoma dojke, posebnih oblika karcinoma pluća (karcinom nemalih stanica pluća), karcinoma prostate, karcinoma želuca ili karcinoma glave i vrata:
Docetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Docetaksel Teva u kombinaciji s doksorubicinom i ciklofosfamidom indiciran je za adjuvantno liječenje bolesnika s:
Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.
Docetaksel Teva u kombinaciji s trastuzumabom indiciran je za liječenje bolesnika s metastatskim karcinomom dojke i prekomjerno izraženim HER2, koji nisu ranije primali kemoterapiju za metastatsku bolest.
Docetaxel Teva is a ‘generic medicine’.
Docetaxel Teva je „generički lijek”.
Docetaxel Teva is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel solutions.
Docetaksel Teva je antineoplastična tvar te se, kao što je slučaj i sa svim ostalim potencijalno toksičnim spojevima, mora s njime oprezno rukovati u pripremi otopine Docetaksela.
Docetaxel Teva is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Teva solutions.
Docetaksel Teva je antineoplastična tvar te se njime, kao što je slučaj i sa svim ostalim potencijalno toksičnim spojevima, mora oprezno rukovati u pripremi Docetaksel Teva otopina.
Docetaxel Teva is indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.
Docetaksel Teva je indiciran za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom nemalih stanica pluća nakon neuspjeha prethodne kemoterapije.
Docetaxel Teva is only used when the neutrophil count (the level of a type of white blood cell) is normal (at least 1,500 cells/mm3.) Dexamethasone (an anti-inflammatory medicine) should also be given to the patient, starting on the day before the Docetaxel Teva infusion.
Docetaxel Teva koristi se samo kad je broj neutrofila (razina vrste leukocita) normalan (najmanje 1 500 stanica/mm3.) Deksmetazon (protuupalni lijek) također treba davati bolesnicima počevši na dan prije infuzije lijeka Docetaxel Teva.
Docetaxel Teva is supplied as single-dose vials.
Docetaksel Teva je dostupan u jednodoznim bočicama.
Docetaxel Teva is used with cisplatin and 5-fluorouracil (other anticancer medicines); head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread).
Docetaxel Teva koristi se s cisplatinom i 5-fluorouracilom (drugim lijekovima protiv karcinoma); karcinoma glave i vrata u bolesnika čiji je karcinom lokalno uznapredovao (karcinom koji je narastao, ali se nije raširio).
Docetaxel Teva must NOT be administered if you are pregnant unless clearly indicated by your doctor.
Docetaksel Teva NE smijete primati ako ste trudni, osim ako to liječnik nije izričito propisao.
Docetaxel was administered as a 1-hour infusion, all other medicinal products were given as intraveinously on day 1 every three weeks.
Docetaksel se primjenjivao u obliku jednosatne infuzije, a svi ostali lijekovi davali su se intravenski na dan 1 svaka tri tjedna.
Docetaxel was administered as a 1-hour infusion, all other medicinal products were given as intravenous bolus on day one.
Docetaksel se primjenjivao u obliku jednosatne infuzije, a svi ostali lijekovi davali su se u intravenskom bolusu
Docetaxel was administered as a 1-hour infusion, all other medicinal products were given intravenously on day 1 every three weeks.
Docetaksela se primjenjivao u obliku jednosatne infuzije, a svi ostali lijekovi davali su se intravenski na dan 1 svaka tri tjedna.
Docetaxel was administered as a 1-hour infusion, all other medicinal products were given intravenously on day 1 every three weeks.
Docetaxel se primjenjivao u obliku jednosatne infuzije, a svi ostali lijekovi davali su se intravenski na dan 1 svaka tri tjedna.
Docetaxel was administered as a 1-hour infusion; all other medicinal products were given as intravenous bolus on day one.
Docetaksel se primjenjivao u obliku jednosatne infuzije, a svi ostali lijekovi davali su se u intravenskom bolusu na dan 1.
Docetaxel was given as an initial dose of 75 mg/m2 IV infusion every three weeks with the option to escalate to 100 mg/m2 at the investigator’s discretion if the initial dose was well tolerated.
Docetaksel se primjenjivao intravenskom infuzijom u početnoj dozi od 75 mg/m2 svaka tri tjedna, koja se prema odluci ispitivača mogla povećati do 100 mg/m2 ako je bolesnica dobro podnijela početnu dozu.
Docetaxel Winthrop 160 mg/8 ml concentrate for solution for infusion docetaxel
Docetaxel Winthrop 160 mg/8 ml koncentrat za otopinu za infuziju docetaksel
Docetaxel Winthrop 160 mg/8 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Winthrop 160 mg/8 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku otopinu.
Docetaxel Winthrop 160 mg/8 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Winthrop 160 mg/8 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku vrećicu.
Docetaxel Winthrop 160 mg/8 ml concentrate for solution for infusion.
Docetaxel Winthrop 160 mg/8 ml koncentrat za otopinu za infuziju
Docetaxel Winthrop 160 mg/8 ml sterile concentrate docetaxel
Docetaxel Winthrop 160 mg/8 ml sterilni koncentrat docetaksel
Docetaxel Winthrop 20 mg/1 ml concentrate for solution for infusion
Docetaxel Winthrop 20 mg/1 ml koncentrat za otopinu za infuziju
Docetaxel Winthrop 20 mg/1 ml concentrate for solution for infusion docetaxel
Docetaxel Winthrop 20 mg/1 ml koncentrat za otopinu za infuziju docetaksel
Docetaxel Winthrop 20 mg/1 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Winthrop 20 mg/1 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku otopinu.